Maximum Weight-Loss Bundle

Maximum Weight-Loss Bundle Overview

Are you focused on Maximum Weight-Loss mechanisms? Clinical studies show this combo had an average weight loss of ~22.7%. This curated quad brings together peptides commonly studied for reducing body and visceral fat, regulating appetite, managing glucose, enhancing performance, lean mass preservation, tissue repair, breaking down stored fats and supporting inflammatory balance—streamlining your protocol into a single, ready-to-use kit.

Why these three peptides together?

• Dual-hormone satiety approach: GLP -1 CS also known as CagriSema pairs a GLP-1 receptor agonist with an amylin analog to study complementary mechanisms for appetite regulation, reduced energy intake, and glycemic markers.
• Targeted fat-metabolism signal: AOD-9604 is frequently investigated for its role in stimulating lipolysis and limiting new fat cell formation—useful for body-composition endpoints.
• Endogenous GH-axis support: Tesamorelin is a GHRH analog used to examine pathways involved in natural growth-hormone and IGF-1 signaling, often linked in literature to lean-mass maintenance, visceral-fat metabolism, and metabolic balance.

This bundle is curated to help investigators examine complementary pathways that literature associates with:

• Adipose metabolism & fat mass – evaluate biomarkers of lipolysis and inhibited lipogenesis (AOD-9604), adipocyte differentiation, fat oxidation, and GH-linked changes in visceral-fat turnover (Tesamorelin).
• Appetite control & energy intake – study GLP-1 receptor and amylin-receptor–mediated satiety signaling, gastric emptying, and hypothalamic pathways (CagriSema).
• Glycemic regulation – investigate insulin secretion/sensitivity markers, post-prandial glucose dynamics, and fasting glucose endpoints relevant to GLP-1 research (CagriSema).

• Lean-mass maintenance & tissue support – examine endogenous GH/IGF-1–related signaling, protein synthesis, cellular repair, and muscle-preservation markers (Tesamorelin).
• Metabolic balance & endocrine rhythm – explore nighttime GH-pulse patterns, circadian influences on metabolic activity, and downstream endocrine markers involved in overall homeostasis (Tesamorelin).

• Inflammatory balance – explore cytokine profiles and oxidative-stress markers associated with improved metabolic health.
• Healthy-aging markers – examine cellular stress-response pathways and mitochondrial resilience often discussed in longevity research contexts.

GLP -1 CS / CagriSema (Cagrilintide + Semaglutide)

Reduces appetite, increases feelings of fullness & manages blood glucose levels.

Cagrilintide is an amylin analog (satiety hormone); semaglutide is a GLP-1 receptor agonist. Together they’re being studied for chronic weight management and type 2 diabetes. In Phase 3 trials (REDEFINE), the combo produced ~22.7% average weight loss at 68 weeks in adults without diabetes and ~15.7% in adults with type 2 diabetes, with improvements in blood sugar and other cardiometabolic measures.

AOD-9604

Reduces fat cell production, breaks down stored fat, increases bone-growth,& cartilage regeneration.

Peptide AOD 9604 is a modified form of amino acids that our bodies naturally create. AOD-9604 is a short peptide derived from the C-terminal region (residues 176–191) of human growth hormone (hGH) with an N-terminal tyrosine modification. AOD-9604’s potential benefits include fat loss by stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat production), potentially leading to a powerful and effective fat burner that works on obese fat cells more than lean cells. It also may have bone-stimulating properties, suggesting a possible role in osteoporosis prevention.

Tesamorelin

Reduces belly fat & fat around organs, increases lean muscle, improved cardiovascular health, cognitive function & immunity.

Tesamorelin is a stabilized growth-hormone–releasing hormone (GHRH) that stimulates endogenous GH → raises IGF-1. It’s FDA-approved to reduce excess abdominal (visceral) fat in people living with HIV. Due to its ability to reduce visceral fat, improve metabolic profiles and cardiovascular health has led to off-label exploration of its potential benefits. Research is ongoing and the benefits claimed are still emerging.

Research-only note: These peptides are not FDA-approved for therapeutic use; published effects are primarily preclinical and exploratory.